Association of mitragynine levels with lipid profiles in regular kratom (Mitragyna speciosa) users

• Kratom users showed lower LDL, urea, creatinine, and higher eGFR than non-users. • Serum mitragynine correlated negatively with LDL and TG levels. • Most users consumed kratom for health, often > 21 leaves daily in concentrated brews. Kratom ( Mitragyna speciosa ) is widely consumed in Southeast Asia for both medicinal and recreational purposes, yet its impact on human health remains unclear. This study examined sociodemographic factors, consumption patterns, serum mitragynine (MG) levels, and clinical chemistry parameters among 90 male participants from the Putussibau District, West Kalimantan, Indonesia. Participants were categorized into kratom users (n = 64) and non-users (n = 26). The majority of users indicated that they consumed kratom for health-related reasons, most commonly for 2–5 years, and nearly half reported daily intake exceeding 21 leaves. Serum MG concentrations were significantly higher among users than non-users, although no associations were observed with duration or intensity of consumption. Clinical chemistry analysis revealed that kratom users had lower levels of LDL, BUN, urea, and creatinine, alongside higher eGFR values, while no significant differences were detected in liver enzymes, glucose, HDL, triglycerides, or inflammatory markers. Notably, serum MG was negatively correlated with LDL and triglyceride levels. Stratified analysis indicated that long-term use was associated with favorable hepatic and lipid profiles, suggesting possible adaptive metabolic responses, whereas higher daily intake produced mild, subclinical elevations in liver and renal markers. Additionally, systemic inflammation, reflected by increased hsCRP and IL-6, was linked to self-reported anxiety, highlighting a potential peripheral mechanism connecting kratom use to central nervous system (CNS) effects. Overall, these findings suggest that regular kratom use may elicit adaptive physiological changes with minimal biochemical perturbation at moderate intake levels. Further longitudinal and mechanistic studies are warranted to clarify causal pathways and long-term health implications of kratom use.

Authors

Institutions

Publication Details

Journal
Medicine in Drug Discovery
Published
2025-11-29
DOI
https://doi.org/10.1016/j.medidd.2025.100241
Primary Topic
Alkaloids: synthesis and pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of mitragynine levels with lipid profiles in regular kratom (Mitragyna speciosa) users

Lola Ayu Istifiani, Weny Lestari, Rohmat Mujahid, Zulvikar Syambani Ulhaq et al.
Medicine in Drug Discovery
Alkaloids: synthesis and pharmacology
article

Association of mitragynine levels with lipid profiles in regular kratom (Mitragyna speciosa) users

Lola Ayu Istifiani, Weny Lestari, Rohmat Mujahid, Zulvikar Syambani Ulhaq, Mery Budiarti, Agung Eru Wibowo, Slamet Wahyono, Lusi Kristiana, Aris Yulianto
article en

Abstract

• Kratom users showed lower LDL, urea, creatinine, and higher eGFR than non-users. • Serum mitragynine correlated negatively with LDL and TG levels. • Most users consumed kratom for health, often > 21 leaves daily in concentrated brews. Kratom ( Mitragyna speciosa ) is widely consumed in Southeast Asia for both medicinal and recreational purposes, yet its impact on human health remains unclear. This study examined sociodemographic factors, consumption patterns, serum mitragynine (MG) levels, and clinical chemistry parameters among 90 male participants from the Putussibau District, West Kalimantan, Indonesia. Participants were categorized into kratom users (n = 64) and non-users (n = 26). The majority of users indicated that they consumed kratom for health-related reasons, most commonly for 2–5 years, and nearly half reported daily intake exceeding 21 leaves. Serum MG concentrations were significantly higher among users than non-users, although no associations were observed with duration or intensity of consumption. Clinical chemistry analysis revealed that kratom users had lower levels of LDL, BUN, urea, and creatinine, alongside higher eGFR values, while no significant differences were detected in liver enzymes, glucose, HDL, triglycerides, or inflammatory markers. Notably, serum MG was negatively correlated with LDL and triglyceride levels. Stratified analysis indicated that long-term use was associated with favorable hepatic and lipid profiles, suggesting possible adaptive metabolic responses, whereas higher daily intake produced mild, subclinical elevations in liver and renal markers. Additionally, systemic inflammation, reflected by increased hsCRP and IL-6, was linked to self-reported anxiety, highlighting a potential peripheral mechanism connecting kratom use to central nervous system (CNS) effects. Overall, these findings suggest that regular kratom use may elicit adaptive physiological changes with minimal biochemical perturbation at moderate intake levels. Further longitudinal and mechanistic studies are warranted to clarify causal pathways and long-term health implications of kratom use.

Medicine in Drug DiscoveryVol. 29
University of Brawijaya (ID), University of Pembangunan Nasional Veteran Jawa Timur (ID), Regional Development Agency (CZ), Indonesian Agency for Agricultural Research and Development (ID), National Nuclear Energy Agency of Indonesia (ID)
Openalex Percentile: Top 54%
Alkaloids: synthesis and pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.